Barbara Dalton has joined Pfizer Inc. as head of its in-house venture capital arm. She previously was a general partner with EuclidSR Partners and, before that, was president of S.R. One, the venture arm of GlaxoSmithKline. The Pfizer venture program does not invest in drug companies, but instead focuses on medical devices, healthcare IT and healthcare services. www.pfizer.com